Humira

Interchangeability Study Initiated for Adalimumab Biosimilar

Interchangeability Study Initiated for Adalimumab Biosimilar

By

Boehringer Ingelheim has initiated a clinical study to investigate the interchangeability between an adalimumab biosimilar candidate and Humira.

Concern Regarding Legislation Allowing Substitution of Biosimilars for Branded Drugs

Concern Regarding Legislation Allowing Substitution of Biosimilars for Branded Drugs

Much concern has been voiced regarding legislation allowing the substitution of biosimilars for branded drugs.

Sign Up for Free e-Newsletters